Barclays Downgrades BioMarin Pharmaceutical Inc. (BMRN) to Equalweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/16/2024
- Dow up on UnitedHealth boost; higher bond yields, Mideast tensions cap gains
- Tesla stock tests 1-year lows as market cap drops below $500 billion
- UnitedHealth (UNH) beats earnings, revenue estimates in Q1; shares up
- BofA profit drops as provisions rise, but beats estimates on investment banking surge
- Morgan Stanley (MS) earnings beat lifts stock
- Trump Media & Technology Group (DJT) Files S-1
- Tesla (TSLA) Senior VP Drew Baglino Is Said To Leave The Company - Bloomberg
- General Motors (GM) Said to be Moving Detroit HQ to Dan Gilbert's Hudson Tower - Bloomberg
- GE HealthCare (GEHC) Announces Resignation of Jan Makela, CEO of Imaging
- The Israeli Air Force Has Completed Its Preparation For An Imminent Attack Against Iran - Reuters
- Morgan Stanley, UnitedHealth and Bank of America rise premarket; Tesla falls
- Morgan Stanley, UnitedHealth and Bank of America rise premarket; Tesla falls
- After-hours movers: Tesla, Gildan Activewear, Macatawa Bank, and more
- Midday movers: Goldman Sachs and Meta Platforms rise; Apple and Tesla fall
- Nike, Alpine Immune Sciences rise premarket; CarMax, Robinhood and Regeneron fall
Nomura Securities Starts BioMarin Pharmaceutical Inc. (BMRN) at Neutral, $75 PT
January 8, 2014 7:56 AM ESTNomura Securities initiates coverage on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) with a Neutral. PT $75.00.
"BioMarin's diversified product portfoliowith four marketed drugs, an advanced pipeline with three drugs in Phase III trials and a focus on high margin ultra orphan diseasessupports our... More
